Pharmaceuticals UK

UK CAR-T Cell Therapy Market Analysis, 2024–2034

UK CAR-T Cell Therapy Market Industry Trends and Forecast to 2034: Segmented by (Target, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

UK · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $148.8 Mn Estimated value
Estimate 2025 $181.1 Mn 2.8% of the global market
Projected 2034 $1.06 Bn 485.6% Adds $879.6 Mn over 9 forecast years
CAGR 2025–2034 21.7% Faster than 92% of 180 Pharmaceuticals markets here
Key players 6 +1
  • UK is 2.8% of the global market.
  • In Europe, the largest is Germany at $244.3 Mn.
  • Fastest growing: Russia at 23.9% a year.
  • UK ranks 3rd of 6 by size in Europe.

Market size projection

UK

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$879.6 Mn total, 2026–2034

Year-by-year market size, 2024–2034
CAR-T Cell Therapy Market market size by year, UK
YearMarket sizeChange that yearSince 2025
2024 (estimate) $148.8 Mn — —
2025 (base) $181.1 Mn +$32.3 Mn —
2026 (forecast) $220.4 Mn +$39.3 Mn +21.7%
2027 (forecast) $268.3 Mn +$47.8 Mn +48.1%
2028 (forecast) $326.5 Mn +$58.2 Mn +80.2%
2029 (forecast) $397.3 Mn +$70.8 Mn +119.4%
2030 (forecast) $483.6 Mn +$86.2 Mn +167%
2031 (forecast) $588.5 Mn +$104.9 Mn +224.9%
2032 (forecast) $716.2 Mn +$127.7 Mn +295.4%
2033 (forecast) $871.6 Mn +$155.4 Mn +381.2%
2034 (forecast) $1.06 Bn +$189.1 Mn +485.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

The UK CAR-T Cell Therapy Market Analysis Executive Summary

CAR-T cell therapy changes a patient's own immune T cells so they can find and kill cancer cells, mainly in blood cancers.

Key segments of the CAR-T Cell Therapy market include target (CD19, BCMA and Others) and indication (Lymphoma, Leukemia and Multiple Myeloma).

UK CAR-T Cell Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the CAR-T Cell Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the CAR-T Cell Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the CAR-T Cell Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for CAR-T Cell Therapy Market in UK

The CAR-T Cell Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for CAR-T Cell Therapy Market in UK

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for CAR-T Cell Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in UK.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in CAR-T Cell Therapy right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

CAR-T Cell Therapy in context

The UK compared

  • Health spending per person: 5,860 US$ per person (2024). World: 1,317 US$ per person (2023). 2nd highest of the 6 countries we cover in Europe.[1]
  • Doctors: 3.30 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 5th highest of the 6 countries we cover in Europe.[2]
  • People aged 65 and over: 19.7% of people (2025). World: 10.4% of people (2025). 5th highest of the 6 countries we cover in Europe.[3]

Questions, answered with public data

How many clinical trials on CAR-T Cell Therapy are running in the UK?
53 studies are recruiting, active or about to start in the UK.[4]
How much research is published on CAR-T Cell Therapy?
PubMed lists 7,618 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the UK. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Back to Catalogue

Related Pharmaceuticals reports in UK

See all

Related on cell and gene therapy and oncology

See the topic